- Home
- CELC vs NMAI Comparison
CELC vs NMAI Comparison
Compare CELC & NMAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CELC
- NMAI
- Stock Information
- Founded
- CELC 2011
- NMAI 2021
- Country
- CELC United States
- NMAI United States
- Employees
- CELC N/A
- NMAI N/A
- Industry
- CELC Medical Specialities
- NMAI Investment Managers
- Sector
- CELC Health Care
- NMAI Finance
- Exchange
- CELC Nasdaq
- NMAI Nasdaq
- Market Cap
- CELC 440.0M
- NMAI 427.2M
- IPO Year
- CELC 2017
- NMAI N/A
- Fundamental
- Price
- CELC $55.07
- NMAI $12.94
- Analyst Decision
- CELC Strong Buy
- NMAI
- Analyst Count
- CELC 5
- NMAI 0
- Target Price
- CELC $53.60
- NMAI N/A
- AVG Volume (30 Days)
- CELC 862.3K
- NMAI 74.8K
- Earning Date
- CELC 11-13-2025
- NMAI 01-01-0001
- Dividend Yield
- CELC N/A
- NMAI 13.14%
- EPS Growth
- CELC N/A
- NMAI N/A
- EPS
- CELC N/A
- NMAI 0.64
- Revenue
- CELC N/A
- NMAI N/A
- Revenue This Year
- CELC N/A
- NMAI N/A
- Revenue Next Year
- CELC N/A
- NMAI N/A
- P/E Ratio
- CELC N/A
- NMAI $19.03
- Revenue Growth
- CELC N/A
- NMAI N/A
- 52 Week Low
- CELC $7.58
- NMAI $10.60
- 52 Week High
- CELC $63.06
- NMAI $12.55
- Technical
- Relative Strength Index (RSI)
- CELC 59.21
- NMAI 64.46
- Support Level
- CELC $50.44
- NMAI $12.51
- Resistance Level
- CELC $63.06
- NMAI $13.05
- Average True Range (ATR)
- CELC 3.03
- NMAI 0.10
- MACD
- CELC -0.90
- NMAI 0.03
- Stochastic Oscillator
- CELC 44.24
- NMAI 79.63
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.
About NMAI Nuveen Multi-Asset Income Fund of Beneficial Interest
Nuveen Multi-Asset Income Fund is a closed-end management investment company. The Fund dynamically invests in a portfolio of equity and debt securities of issuers located around the world. This dynamic investment uses a risk-based framework in which any amount can be allocated to an asset-class at any time. The Fund may invest in equity and debt securities of any type without limit.